MenC conjugate vaccination, Memory B cells, infectious diseases, meningitis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Good general health; 2. Provision of written informed consent; 3. Adherent to protocol, and available during the study period
Exclusion criteria
Exclusion criteria: 1. Severe acute (infectious) illness of fever (>38.5°C) within 2 weeks before vaccination; 2. Present evidence of serious disease(s) demanding medical treatment that might interfere the results of the study; 3. Known or suspected allergy to any of the vaccine components (by medical history); 4. Known or suspected immune deficiency; 5. History of any neurologic disorder, including epilepsy; 6. Previous administration of plasma products (including immunoglobulins) within the last 6 months; 7. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - How long does B-cell memory persist after a single conjugate MenC vaccination in adults and which cells are involved? | — |
Secondary
| Measure | Time frame |
|---|---|
| - How long do serum SBA titers persist in time after a single vaccination with the conjugate MenC vaccine? - Despite decline of antibody concentrations in the years after vaccination, do memory B-cells persist? - Antibody kinetics, it is important to follow the rise of antibody titers after vaccination: o How long will it take before serum IgG antibodies are detectable and/or rise after primary- or booster vaccination? o What is the avidity of serum IgG antibodies compared to the primary and booster vaccination? - In what time period after primary vaccination with MenC are memory B-cells formed and how rapidly do memory B-cells expand after booster vaccination? - Are there differences (antibody titer levels, IgG subclass distribution and serum antibody avidity) in booster responses between a booster vaccination using the conjugate MenC vaccine or plain serogroup C capsular polysaccharide . | — |
Contacts
RIVM, afd. LIS Postbus 1